

# Cecilia Carpio

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2081808/publications.pdf>

Version: 2024-02-01

33  
papers

750  
citations

623734

14  
h-index

642732

23  
g-index

33  
all docs

33  
docs citations

33  
times ranked

1188  
citing authors

#	ARTICLE	IF	CITATIONS
1	Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type <i>TP53</i> Solid Tumors and Acute Leukemia. <i>Clinical Cancer Research</i> , 2022, 28, 870-881.	7.0	32
2	Neurotoxicity-associated sinus bradycardia after chimeric antigen receptor T-cell therapy. <i>Hematological Oncology</i> , 2022, , .	1.7	2
3	The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL. , 2022, 10, e004475.		50
4	Cell free circulating tumor DNA in cerebrospinal fluid detects and monitors central nervous system involvement of B-cell lymphomas. <i>Haematologica</i> , 2021, 106, 513-521.	3.5	75
5	Clinical and pathological characteristics of peripheral T-cell lymphomas in a Spanish population: a retrospective study. <i>British Journal of Haematology</i> , 2021, 192, 82-99.	2.5	5
6	Biomarkers of response to ibrutinib plus nivolumab in relapsed diffuse large B-cell lymphoma, follicular lymphoma, or Richter's transformation. <i>Translational Oncology</i> , 2021, 14, 100977.	3.7	13
7	Selection process and causes of non-eligibility for CD19 CAR-T cell therapy in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma in a European center. <i>Leukemia and Lymphoma</i> , 2021, 62, 2288-2291.	1.3	1
8	Prognostic impact of total metabolic tumor volume in large B-cell lymphoma patients receiving CAR T-cell therapy. <i>Annals of Hematology</i> , 2021, 100, 2303-2310.	1.8	32
9	Early Relapse after First Line Has a Significant Impact on Overall Survival in Patients with Mantle Cell Lymphoma (MCL). <i>Blood</i> , 2021, 138, 1357-1357.	1.4	1
10	The CAR-Hematotox Identifies Patients at High Risk for Prolonged Neutropenia, Infectious Complications and Prolonged Hospitalization Following CD19-CART in R/R LBCL. <i>Blood</i> , 2021, 138, 3852-3852.	1.4	1
11	First-in-Human Phase I Study of Iadademstat (ORY-1001): A First-in-Class Lysine-Specific Histone Demethylase 1A Inhibitor, in Relapsed or Refractory Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2020, 38, 4260-4273.	1.6	59
12	Avadomide monotherapy in relapsed/refractory DLBCL: safety, efficacy, and a predictive gene classifier. <i>Blood</i> , 2020, 135, 996-1007.	1.4	49
13	Potential Survival Benefit for Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation after Nivolumab Therapy for Relapse/Refractory Hodgkin Lymphoma: Real-Life Experience in Spain. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1534-1542.	2.0	18
14	Urelumab alone or in combination with rituximab in patients with relapsed or refractory B-cell lymphoma. <i>American Journal of Hematology</i> , 2020, 95, 510-520.	4.1	56
15	Phase I Study of TAK-659, an Investigational, Dual SYK/FLT3 Inhibitor, in Patients with B-Cell Lymphoma. <i>Clinical Cancer Research</i> , 2020, 26, 3546-3556.	7.0	13
16	A Phase 2 Study of Odronextamab (REGN1979), a CD20 x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma. <i>Blood</i> , 2020, 136, 28-29.	1.4	9
17	Infection Risk in Lymphoproliferative Diseases (LPD) Treated with Targeted Drugs. <i>Geltamo Real-Life Experience</i> . <i>Blood</i> , 2020, 136, 37-40.	1.4	0
18	Prognostic Impact of Metabolic Tumor Burden in Large B-Cell Lymphoma Patients Receiving CAR T-Cell Therapy. <i>Blood</i> , 2020, 136, 27-29.	1.4	0

#	ARTICLE	IF	CITATIONS
19	Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Hematologic Patients: Experience at the Hospital Attending More Patients in Spain. <i>Blood</i> , 2020, 136, 30-31.	1.4	0
20	Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study. <i>Lancet Haematology</i> , 2019, 6, e67-e78.	4.6	146
21	Promising activity of selinexor in the treatment of a patient with refractory diffuse large B-cell lymphoma and central nervous system involvement. <i>Haematologica</i> , 2018, 103, e92-e93.	3.5	18
22	Peripheral T-Cell Lymphomas in Spain: Profiling Clinical, Phenotypic and Genetic Characteristics in Spanish Population. <i>Blood</i> , 2018, 132, 2938-2938.	1.4	0
23	Microenvironment regulates the expression of miR-21 and tumor suppressor genes PTEN, PIAS3 and PDCD4 through ZAP-70 in chronic lymphocytic leukemia. <i>Scientific Reports</i> , 2017, 7, 12262.	3.3	26
24	Safety and Efficacy of the Combination of Ibrutinib and Nivolumab in Patients with Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia. <i>Blood</i> , 2017, 130, 833-833.	1.4	12
25	Inhibition of BCR signaling using the Syk inhibitor TAK-659 prevents stroma-mediated signaling in chronic lymphocytic leukemia cells. <i>Oncotarget</i> , 2017, 8, 742-756.	1.8	20
26	Updated Results from a Phase 1 Study of TAK-659, an Investigational and Reversible SYK Inhibitor, in Patients (Pts) with Advanced Solid Tumor or Lymphoma Malignancies. <i>Blood</i> , 2016, 128, 624-624.	1.4	8
27	Co-culture of primary CLL cells with bone marrow mesenchymal cells, CD40 ligand and CpG ODN promotes proliferation of chemoresistant CLL cells phenotypically comparable to those proliferating in vivo. <i>Oncotarget</i> , 2015, 6, 7632-7643.	1.8	41
28	ZAP-70 Promotes the Infiltration of Malignant B-Lymphocytes into the Bone Marrow by Enhancing Signaling and Migration after CXCR4 Stimulation. <i>PLoS ONE</i> , 2013, 8, e81221.	2.5	15
29	The Co-Culture Of Primary CLL Cells With Bone Marrow Mesenchymal Cells, CD40 Ligand and CpG ODN Promotes The Proliferation Of Chemoresistant CLL Cells Phenotypically Comparable To Those From The Proliferative Centers. <i>Blood</i> , 2013, 122, 4153-4153.	1.4	0
30	YM155, a Small-Molecule Survivin Suppressant, Mainly Targets Primary CLL Cells Actively Proliferating and Overcomes Microenvironment-Mediated CLL Cell Protection. <i>Blood</i> , 2012, 120, 3868-3868.	1.4	0
31	ZAP-70 Enhances Infiltration of Malignant B Lymphocytes Into the Bone Marrow by Increasing Migratory and Survival Responses to CXCR4 Stimulation. <i>Blood</i> , 2012, 120, 1779-1779.	1.4	0
32	ZAP-70 enhances migration of malignant B lymphocytes toward CCL21 by inducing CCR7 expression via IgM-ERK1/2 activation. <i>Blood</i> , 2011, 118, 4401-4410.	1.4	48
33	ZAP-70 Enhances Migration of Malignant B Cells towards Lymphoid Organs in a Burkitt Lymphoma Xenograft Model. <i>Blood</i> , 2011, 118, 2844-2844.	1.4	0